Trial Profile

Tau protein targeting therapeutics for the treatment of neurodegeneration.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 03 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tau protein degraders (Primary)
Indications Neurodegenerative disorders
Focus Therapeutic Use

Most Recent Events

03 May 2024 New trial record
30 Apr 2024 According to Beyondspring Inc media release, its subsidiary Seed therapeutics Achieves Second and Third Molecular Glue Discovery Milestones in the Eli Lilly R&D Collaboration;has declared an IND Candidate status, targeting first human dose in 1H 2025 and plans IND Candidate status for the Tau Project in 2H 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com